We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV Financial
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca PLC (AZN - Free Report) , Linde plc (LIN - Free Report) , Eaton Corp. plc (ETN - Free Report) , Franklin Financial Services Corp. (FRAF - Free Report) and BV Financial, Inc. (BVFL - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for AstraZeneca, Linde & Eaton
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC, Linde plc and Eaton Corp. plc, as well as two micro-cap stocks Franklin Financial Services Corp. and BV Financial, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of AstraZeneca have gained +3.8% over the past year against the Zacks Medical - Biomedical and Genetics industry’s gain of +7.1%. The company’s Q3 earnings and sales beat estimates. It has a diverse product portfolio and global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra should keep driving revenues. New drugs are also contributing to growth.
In 2026, AstraZeneca has gained approval for four new medicines, Etcamah and Baxfendy in the United States and Klygefa and Amlypave in Japan. AstraZeneca’s pipeline is also strong, with several pivotal data readouts lined up for 2027. Backed by its new products and pipeline drugs, AstraZeneca expects to generate $80 billion in total revenues by 2030.
However, AstraZeneca’s several blockbuster drugs like Farxiga, Brilinta, Symbicort and Soliris have lost patent exclusivity and are facing generic erosion. Also, effects from volume-based procurement are hurting sales in China.
Linde’s shares have outperformed the Zacks Chemical - Specialty industry over the past year (+27.9% vs. +19.2%). The company’s long-term supply contracts and diverse industrial gas customers support recurring cash flows despite uneven demand. Its project backlog provides visibility into future sales, while semiconductor investment supports electronics growth.
Pricing discipline and productivity initiatives are helping the core gases business sustain earnings growth. Restructuring actions offer opportunities to improve profitability through 2027.
However, sluggish European manufacturing and weak Chinese domestic consumption could constrain industrial gas volumes. Lincare remains a drag on earnings, while equipment mix and helium-related costs weigh on Asia-Pacific margins. Energy inflation and delayed cost recovery add uncertainty. The Neutral view balances contracted growth and execution opportunities against uneven demand and margin risks.
Shares of Eaton have gained +0.8% over the past year against the Zacks Manufacturing - Electronics industry’s gain of +10.3%. The company’s third-quarter earnings exceeded expectations, supported by electrification investments, data center expansion and aerospace demand. Capacity additions are converting strong orders into sales and improving Electrical Americas margins.
Acquisitions, including Boyd Thermal, strengthen its capabilities, while the planned Mobility separation should sharpen its portfolio. Raised earnings guidance improves visibility, and revenues are projected to grow through 2028. The Zacks model projects total revenues to improve in the 2026-2028 period.
However, rising debt, interest expenses, integration challenges and commodity costs could pressure profitability. Supply-chain disruptions, technology risks and project delays add uncertainty. These factors support a balanced investment outlook.
Franklin Financial Services’ shares have outperformed the Zacks Banks - Northeast industry over the past year (+47.4% vs. +33.8%). This microcap company with a market capitalization of $311 million, has an investment case which rests on a growing core deposit base, improving funding costs and expense discipline that support loan growth and stronger operating earnings. Its commercial real estate franchise provides scale, while lower concentration and a smaller watch list temper credit concerns.
Wealth management adds recurring fee income, and retained earnings strengthen regulatory capital and distribution capacity. Deposit growth has also expanded liquidity without additional wholesale borrowing. These drivers support earnings improvement, although property workouts remain unresolved.
However, construction exposure, a new reserve on a letter of credit and an approaching borrowing maturity warrant attention. Larger securities losses have interrupted tangible book value growth and constrain balance-sheet flexibility.
Shares of BV Financial have gained +23.6% over the past year against the Zacks Banks - Northeast industry’s gain of +33.8%. This microcap company with a market capitalization of $175.43 million has seen its loans remain below year-end 2025 levels, and higher deposit costs have pressured quarterly net interest income. Elevated nonperforming loans, heavy real estate exposure and weaker operating cash flow pose risks.
Lower fee income and nine-month expense growth further constrain profitability. Sustained upside depends on disciplined loan growth, stable funding costs and credit quality. Nevertheless, lower borrowing costs and wider net interest margin support earnings, while the loan portfolio's recovery from June offers scope for higher-yielding reinvestment.
Strong regulatory capital, available borrowing capacity, stable deposits and ongoing share repurchases provide financial flexibility and potential per-share gains. Third-quarter expense reductions and modest sequential improvement in nonperforming loans add support.
Image: Bigstock
The Zacks Analyst Blog Highlights AstraZeneca, Linde, Eaton, Franklin and BV Financial
For Immediate Release
Chicago, IL – November 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca PLC (AZN - Free Report) , Linde plc (LIN - Free Report) , Eaton Corp. plc (ETN - Free Report) , Franklin Financial Services Corp. (FRAF - Free Report) and BV Financial, Inc. (BVFL - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Research Reports for AstraZeneca, Linde & Eaton
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC, Linde plc and Eaton Corp. plc, as well as two micro-cap stocks Franklin Financial Services Corp. and BV Financial, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Today's Featured Research Reports
Shares of AstraZeneca have gained +3.8% over the past year against the Zacks Medical - Biomedical and Genetics industry’s gain of +7.1%. The company’s Q3 earnings and sales beat estimates. It has a diverse product portfolio and global footprint. Its key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra should keep driving revenues. New drugs are also contributing to growth.
In 2026, AstraZeneca has gained approval for four new medicines, Etcamah and Baxfendy in the United States and Klygefa and Amlypave in Japan. AstraZeneca’s pipeline is also strong, with several pivotal data readouts lined up for 2027. Backed by its new products and pipeline drugs, AstraZeneca expects to generate $80 billion in total revenues by 2030.
However, AstraZeneca’s several blockbuster drugs like Farxiga, Brilinta, Symbicort and Soliris have lost patent exclusivity and are facing generic erosion. Also, effects from volume-based procurement are hurting sales in China.
(You can read the full research report on AstraZeneca here >>>)
Linde’s shares have outperformed the Zacks Chemical - Specialty industry over the past year (+27.9% vs. +19.2%). The company’s long-term supply contracts and diverse industrial gas customers support recurring cash flows despite uneven demand. Its project backlog provides visibility into future sales, while semiconductor investment supports electronics growth.
Pricing discipline and productivity initiatives are helping the core gases business sustain earnings growth. Restructuring actions offer opportunities to improve profitability through 2027.
However, sluggish European manufacturing and weak Chinese domestic consumption could constrain industrial gas volumes. Lincare remains a drag on earnings, while equipment mix and helium-related costs weigh on Asia-Pacific margins. Energy inflation and delayed cost recovery add uncertainty. The Neutral view balances contracted growth and execution opportunities against uneven demand and margin risks.
(You can read the full research report on Linde here >>>)
Shares of Eaton have gained +0.8% over the past year against the Zacks Manufacturing - Electronics industry’s gain of +10.3%. The company’s third-quarter earnings exceeded expectations, supported by electrification investments, data center expansion and aerospace demand. Capacity additions are converting strong orders into sales and improving Electrical Americas margins.
Acquisitions, including Boyd Thermal, strengthen its capabilities, while the planned Mobility separation should sharpen its portfolio. Raised earnings guidance improves visibility, and revenues are projected to grow through 2028. The Zacks model projects total revenues to improve in the 2026-2028 period.
However, rising debt, interest expenses, integration challenges and commodity costs could pressure profitability. Supply-chain disruptions, technology risks and project delays add uncertainty. These factors support a balanced investment outlook.
(You can read the full research report on Eaton here >>>)
Franklin Financial Services’ shares have outperformed the Zacks Banks - Northeast industry over the past year (+47.4% vs. +33.8%). This microcap company with a market capitalization of $311 million, has an investment case which rests on a growing core deposit base, improving funding costs and expense discipline that support loan growth and stronger operating earnings. Its commercial real estate franchise provides scale, while lower concentration and a smaller watch list temper credit concerns.
Wealth management adds recurring fee income, and retained earnings strengthen regulatory capital and distribution capacity. Deposit growth has also expanded liquidity without additional wholesale borrowing. These drivers support earnings improvement, although property workouts remain unresolved.
However, construction exposure, a new reserve on a letter of credit and an approaching borrowing maturity warrant attention. Larger securities losses have interrupted tangible book value growth and constrain balance-sheet flexibility.
(You can read the full research report on Franklin Financial Services here >>>)
Shares of BV Financial have gained +23.6% over the past year against the Zacks Banks - Northeast industry’s gain of +33.8%. This microcap company with a market capitalization of $175.43 million has seen its loans remain below year-end 2025 levels, and higher deposit costs have pressured quarterly net interest income. Elevated nonperforming loans, heavy real estate exposure and weaker operating cash flow pose risks.
Lower fee income and nine-month expense growth further constrain profitability. Sustained upside depends on disciplined loan growth, stable funding costs and credit quality. Nevertheless, lower borrowing costs and wider net interest margin support earnings, while the loan portfolio's recovery from June offers scope for higher-yielding reinvestment.
Strong regulatory capital, available borrowing capacity, stable deposits and ongoing share repurchases provide financial flexibility and potential per-share gains. Third-quarter expense reductions and modest sequential improvement in nonperforming loans add support.
(You can read the full research report on BV Financial here >>>)